<DOC>
	<DOCNO>NCT01240356</DOCNO>
	<brief_summary>The purpose CLOTBUST-HF determine safety novel , external Hands-Free transcranial Doppler ( TCD ) ultrasound system healthy volunteer ischemic stroke patient . If find safe , widespread use operator-independent , ultrasound-enhanced thrombolysis allow plan large Phase III efficacy trial .</brief_summary>
	<brief_title>CLOTBUST Hands-Free : A Phase I/II Pilot Safety Trial</brief_title>
	<detailed_description>Ultrasound energy enhance intravenous rt-PA thrombolysis promise novel treatment modality ischemic stroke . Despite encouraging safety data utilize diagnostic frequency transcranial Doppler ( TCD ) ultrasound , lack widespread availability train personnel limited application . - The primary specific aim pilot phase I/II study ass safety novel , external Hands-Free TCD ultrasound system . Safety new Hands-Free TCD system first assess healthy volunteer . Safety participant determine detailed neurological dermatological exam MRI image brain . Next , safety device evaluate two distinct set acute ischemic stroke patient : 0-3 hour patient treated standard IV rt-PA 3-6 hour non-lytic , image-selected patient treat sonolysis ( without intravenous microbubbles ) . Among healthy volunteer primary measure safety detectable change detail neurological exam blood- brain barrier ( BBB ) disruption change permeability . Among 0-3 hour 3-6 hour group primary measure safety tolerate great 10 % rate symptomatic intracerebral hemorrhage ( sICH ) within 24 hour . * The primary hypothesis replace conventional TCD ultrasound hand-held TCD technology Hands-Free system safe healthy volunteer well acute ischemic stroke patient . If device find safe either 0-3 hour 3-6 hour group , - secondary aim study explore rate arterial recanalization 0-3 hour and/or 3-6 hour group , favorable outcome , clinical recovery . The secondary aim assess hypothesis Hands-Free TCD display similar recanalization early clinical recovery rate compare available historical diagnostic TCD ultrasound control expose conventional FDA-approved TCD technology . Data generate phase I/II trial evaluate safety replace operator-dependent TCD device operator-independent unit . In turn , allow extensive availability therapeutic ultrasound improve enrollment ultrasound-enhanced thrombolysis stroke trial .</detailed_description>
	<criteria>INCLUSION CRITERIA : Phase I Safety ( healthy volunteer ) : Presence temporal window measure first FDAapproved diagnostic TCD device . Age ≥ 18 year old . Signed informed consent . Phase II ( 03 hour ischemic stroke patient ) : Disabling focal neurological deficit ( NIHSS &gt; 4 point ) ; No evidence hemorrhage noncontrast head CT scan ; Intravenous rtPA ( 0.9 mg/kg , 10 % bolus 90 % infusion 1 hour , maximum dose 90 mg ) infusion initiate within 3 hour symptom onset ; Diagnostic TCD complete HFTCD place rtPA bolus . Diagnostic TCD confirm intracranial arterial occlusion middle cerebral artery ( MCA ) , anterior cerebral artery ( ACA ) , internal carotid artery ( ICA ) , posterior cerebral artery ( PCA ) distal basilar artery . Age ≥ 18 year old . Signed informed consent . Phase II ( 36 hour ischemic stroke patient ) : Measurable focal neurological deficit ( NIHSS &gt; 4 point ) ; No evidence hemorrhage noncontrast head CT scan ; Diagnostic TCD confirm intracranial arterial occlusion middle cerebral artery ( MCA ) , anterior cerebral artery ( ACA ) , internal carotid artery ( ICA ) , posterior cerebral artery ( PCA ) distal basilar artery . Presence neuroimaging define mismatch ( CT MRI prior enrollment ) 1 . CTperfusion ≥ 20 % difference affected territory Time Peak ( TTP ) Cerebral Blood Volume ( CBV ) map . 2 . MRI DiffusionPerfusion mismatch ≥ 20 % difference diffusionweighted imaging ( DWI ) lesion territory perfusion delay perfusion weight imaging ( PWI ) . Age ≥ 18 year old . Signed informed consent . EXCLUSION CRITERIA : Phase I Safety ( healthy volunteer ) : History neurological disease affect central nervous system ; Lack temporal window . History renal disease glomerular filtration rate ( GFR ) &lt; 60 . Contraindication MRI ( e.g. , pacemaker , spinal cord stimulator , severe claustrophobia ) Phase II ( 03 hour ischemic stroke patient ) : Absent temporal window patient anterior circulation ischemia ; Intraarterial thrombolysis ; Patient refusal give inform consent participate CLOTBUSTHF trial ; Contraindications intravenous rtPA ( NINDS rtPA Stroke Study Protocol ) 2 . Phase II ( 36 hour ischemic stroke patient ) : Absent temporal window patient anterior circulation ischemia ; Intraarterial thrombolysis ; Patient refusal give inform consent participate CLOTBUSTHF trial ; History allergic response Definity® microspheres microbubbles currently test ( MRX801 ) ; Baseline image consistent malignant ischemic pattern ( low CBV value DWI territory &gt; 100cc tissue ) ; Baseline MRI image demonstrate delay perfusion &gt; 8 second &gt; 100cc brain parenchyma26 ; Patients receive investigational drug , procedure , therapy within 30 day prior study treatment ; Significant concurrent medical/neurological condition deviation normal laboratory test value baseline , opinion investigator , pose significant risk patient warrant exclusion study ; Known severe chronic obstructive pulmonary disease ( COPD ) ( baseline oxygen saturation &lt; 80 % room air ) ; Known righttoleft cardiac shunt .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>transcranial doppler</keyword>
	<keyword>sonothrombolysis</keyword>
	<keyword>ultrasound</keyword>
	<keyword>stroke</keyword>
</DOC>